Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers

Hye Soo Kim, Oidov Baatarkhuu, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kijun Song, Kwang Hyub Han, Beom Kyung Kim, Seung Up Kim

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background & Aims: We compared the risk of hepatocellular carcinoma (HCC) development between patients with chronic hepatitis B (CHB) who achieved virological response (VR; HBV-DNA < 2000 IU/mL) with nucleos(t)ide analogues (NUCs) treatment (NUC-VR group) and patients with inactive CHB phase (ICHBP group). Methods: To adjust for imbalances between NUC-VR and ICHBP groups, propensity score matching (PSM) models with 1:1 ratios were performed. Results: This study included 2032 patients (n = 1291 in NUC-VR group and n = 741 in ICHBP group). Before PSM, NUC-VR group was at higher risk of HCC development than ICHBP group at 7 years (9.4% in NUC-VR group vs 3.3% in ICHBP group; P < 0.001). However, after PSM, the cumulative HCC development rates at 7 years were similar in NUC-VR and ICHBP groups using the three PSM models [2.0% vs 4.3%, PSM model-1 (612 pairs); 3.7% vs 4.4%, PSM model-2 (618 pairs); and 2.4% vs 4.3%, PSM model-3 (610 pairs)] (all P > 0.05). Conclusions: After adjusting heavier hepatic fibrosis burden in NUC-VR group, overall clinical outcomes between 2 groups had become comparable. Therefore, if appropriate, NUCs to prevent viral replication and hepatic inflammation are required for achieving better prognosis.

Original languageEnglish
Pages (from-to)81-89
Number of pages9
JournalLiver International
Volume39
Issue number1
DOIs
Publication statusPublished - 2019 Jan

Bibliographical note

Funding Information:
This study was supported in part by the Ministry of Science, ICT & Future Planning (2016R1A1A1A05005138) and by Research of Korea Centers for Disease Control and Prevention (2016-ER5103-01). The funders had no role in study design, data collection and analysis, or preparation of the manuscript.

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint Dive into the research topics of 'Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers'. Together they form a unique fingerprint.

Cite this